Saturday 17 October 2026
Export ANNX’s income statement to Excel — free account
Annexon, Inc.
ANNX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.7% and free cash flow fell 26.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.41
0.19
−5.28%
Follow ANNX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(84.74%) | (82.63%) | (88.48%) | (105.26%) | |
| (68.72%) | (66.45%) | (70.09%) | (79.38%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(130.23%) | (99.22%) | (97.97%) | (110.18%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.18) | (1.20) | (0.94) | (0.96) | |
Free Cash Flow |
(176.59) | (186.49) | (183.10) | (193.23) | |
Capital Expenditures |
(0.14) | (0.14) | — | (0.20) | |
| Other line items | |||||
Cash ROIC |
(50.43%) | (41.44%) | (42.62%) | (48.88%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.84 | 0.89 | 0.92 | 0.95 | |
Depreciation/Fixed assets |
0.19 | 0.20 | 0.21 | 0.22 | |
Capex/Depreciation |
(0.07) | (0.06) | 0.00 | (0.09) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.18) | (1.20) | (0.94) | (0.96) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates